Compare CSPI & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSPI | CNTX |
|---|---|---|
| Founded | 1968 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.8M | 116.7M |
| IPO Year | 1987 | 2021 |
| Metric | CSPI | CNTX |
|---|---|---|
| Price | $13.01 | $1.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $5.67 |
| AVG Volume (30 Days) | 23.2K | ★ 722.0K |
| Earning Date | 12-16-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $58,730,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $9.65 | $0.49 |
| 52 Week High | $21.95 | $1.55 |
| Indicator | CSPI | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.63 | 49.78 |
| Support Level | $12.74 | $1.08 |
| Resistance Level | $13.78 | $1.34 |
| Average True Range (ATR) | 0.96 | 0.10 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 30.79 | 35.90 |
CSP Inc develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems. The firm operates in two segments, namely Technology Solutions, where the company focuses on value-added reseller integrated solutions, including third-party hardware, software, and technical computer-related consulting, and High-Performance Products segments, where the company designs, manufactures, and delivers products and services to customers that require specialized cybersecurity services, networking, and signal processing. It generates a majority of its revenue from the Technology Solutions segment. Geographically, the company generates the majority of its revenue from the Americas.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.